doi: 10.3324/haematol.2009.016956.
Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment
- PMID: 20139394
- PMCID: PMC2817041
- DOI: 10.3324/haematol.2009.016956
Item in Clipboard
Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment
Haematologica.
2010 Feb.
No abstract available
Similar articles
-
Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil.Am J Nephrol. 2002 Sep-Dec;22(5-6):569-72. doi: 10.1159/000065276. Am J Nephrol. 2002. PMID: 12381961
-
Using mycophenolate mofetil in steroid-resistant nephrotic syndrome.Iran J Kidney Dis. 2012 Sep;6(5):323-5. Iran J Kidney Dis. 2012. PMID: 22976252 No abstract available.
-
[Response to mycophenolate mofetil in a case of lupus nephropathy resistant to cyclophosphamide IV and cyclosporin A].Nefrologia. 2001 Sep-Oct;21(5):516-7. Nefrologia. 2001. PMID: 11795027 Spanish. No abstract available.
-
[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013. Hautarzt. 2000. PMID: 10743574 Review. German.
-
Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.Clin Lymphoma. 2005 Jun;6(1):52-5. doi: 10.3816/clm.2005.n.029. Clin Lymphoma. 2005. PMID: 15989709 Review. No abstract available.
Cited by
-
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.Pharmacol Res Perspect. 2016 Jan 28;4(1):e00206. doi: 10.1002/prp2.206. eCollection 2016 Feb. Pharmacol Res Perspect. 2016. PMID: 26977297 Free PMC article.
-
Immune Mechanisms in Myelodysplastic Syndrome.Int J Mol Sci. 2016 Jun 15;17(6):944. doi: 10.3390/ijms17060944. Int J Mol Sci. 2016. PMID: 27314337 Free PMC article. Review.
-
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.Haematologica. 2020 Jan;105(1):102-111. doi: 10.3324/haematol.2019.219345. Epub 2019 Apr 19. Haematologica. 2020. PMID: 31004015 Free PMC article.
References
-
- Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89(12):4248–67. - PubMed
-
- Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–603. - PubMed
-
- Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037–46. - PubMed
-
- Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez Fuertes I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica. 1999;84(12):1058–64. - PubMed
-
- Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803–11. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
